Conclusions
T2DM
SECONDARY
In conclusion, our pilot randomised controlled trial showed that the addition of the GLP-1 agonist receptor liraglutide after LABG did not significantly improve HbA1c or weight compared to placebo at 6 months. Importantly this trial was underpowered to detect a significant difference between groups in the primary and secondary endpoints. Results are limited by the relatively small sample size and the sub-optimal number of band-adjustments which is, in part, related to the COVID pandemic and may underpin the sub-optimal weight and glycaemic responses in both groups. Future larger randomised controlled trials of longer duration, more intensive LAGB follow-up and with more effective agents (i.e. semaglutide, tirzepatide) are required to confirm whether adjunctive GLP-1 agonist therapy and other gut hormone therapies are beneficial post-metabolic surgery in patients with T2DM.